In the BioHarmony Drug Report Database

"Preview" Icon

Gemcitabine

Gemcitabine, Gemzar, Infugem, Dacogen (gemcitabine) is a small molecule pharmaceutical. Gemcitabine was first approved as Gemcitabine on 1996-05-15. It is used to treat breast neoplasms, non-small-cell lung carcinoma, ovarian neoplasms, and pancreatic ductal carcinoma in the USA. It has been approved in Europe to treat myeloid leukemia. The pharmaceutical is active against ribonucleoside-diphosphate reductase subunit M2 and ribonucleoside-diphosphate reductase large subunit. Gemzar’s patent is valid until 2033-07-01 (FDA).

 

Trade Name

 

Dacogen
 

Common Name

 

gemcitabine
 

ChEMBL ID

 

CHEMBL888
 

Indication

 

breast neoplasms, myeloid leukemia, non-small-cell lung carcinoma, ovarian neoplasms, pancreatic ductal carcinoma
 

Drug Class

 

Nucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives

Image (chem structure or protein)

Gemcitabine structure rendering